生物制药的必由之路：艾意凯咨询关于创新、增长与竞争优势的洞察

The Biopharma Imperative L.E.K. Insights on Innovation, Growth, andCompetitive Advantage Foreword This collection brings together a focused selection of L.E.K. Consulting’s perspectiveson the forces reshaping life sciences and biopharma. The sector continues to push at theboundaries of scientific possibility whi le navigating capit al constraints, acceleratingcompetition and rising expectations from patients, regulators and investors. The piecesincluded here examine those pressures with clarity and offer practical guidance on howleaders can respond with confidence. Our insights highlight the strategic consequences of rapid advances in areas such asradiotherapeutics, next—generation oncology partnerships, AI and quantum computing. Wealso explore the commercial realities facing organisations as they compete in fast—movingtherapeutic markets, reassess portfolio priorities, raise R&D productivity and operate in amore selective funding environment. Across these topics, a consistent message emerges:competitive advantage will rest with organisations that pair scientific ambition withdisciplined decision—making and operational focus. At L.E.K., we help clients interpret change and convert it into decisive action. By distillingmarket signals, emerging opportunities and the pressure points that matter most, thiscollection offers leaders a clear view of what it takes to steer successfully through a periodof structural shifts. Helen Chen Global Sector Co-Head for HealthcareGreater China Managing Partner Contents XÒÎÒÝæýæýÞæăďã¹Ēü¹XΥUĒăÎğÈĜæŖæĜŝ˹DÒŗ0ýĕæÞãĜĕ¹ýÎ[ĜĒ¹ĜÒÞæÒĕ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɢX¹ÎæăĜãÒĒ¹ďÒğĜæÈĕăýĜãÒXæĕÒ˹ÎÎĒÒĕĕæýÞ[ğďď÷ŝã¹æýăüď÷ÒŜæĜŝ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɩ>¹ğýÈãæýÞDăŖÒ÷ŜÝăĒIýÈă÷ăÞŝ˹ɨ[ĜĒ¹ĜÒÞæÒĕÝăĒæăďã¹Ēü¹ăüď¹ýæÒĕ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɢɧWğ¹ýĜğüăüďğĜæýÞæýæăďã¹Ēü¹˹'ğĜğĒÒUĒăĕďÒÈĜĕ¹ýÎ[ĜĒ¹ĜÒÞæÈ0ýĕæÞãĜĕ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɣɧIďĜæüæŢæýÞæăďã¹Ēü¹IďÒĒ¹ĜæăýĕÝăĒ[ĜĒ¹ĜÒÞæÈ(ĒăŗĜã˷˷˷˷˷˷˷˷˷˷˷ɤɪbãÒX¹ÈÒæĕIý˹qæýýæýÞ[ü¹ĒĜæýĜãÒ0ýĜÒýĕæÝŝæýÞ(>U̚ɢC¹ĒõÒĜæýãæý¹˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɥɣ-ăŗUã¹Ēü¹ăüď¹ýæÒĕĒÒĒæŖæýÞĜãÒDÒŜĜq¹ŖÒăÝXÒŖÒýğÒ(ĒăŗĜã˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɦɧIďĜæüæŢæýÞUã¹Ēü¹ÈÒğĜæȹ÷UăĒĜÝă÷æăĕbãĒăğÞãCΥ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɧɣ'æĒĕĜŖĕ˷ÒĕĜæý÷¹ĕĕ̝[æüď÷æÝŝæýÞĜãÒđğ¹ĜæăýÝăĒæăďã¹Ēü¹˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɨɦUĒÒď¹ĒæýÞÝăĒ0ýýăŖ¹Ĝæăý˹C¹ĜğĒæĜŝ'Ē¹üÒŗăĒõÝăĒĒĜæÝæÈæ¹÷0ýĜÒ÷÷æÞÒýÈÒæý>æÝÒ[ÈæÒýÈÒ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɩɣ1.2.3.4.5.6.7.8.9.10. Contents 11.12.13.IýÈă÷ăÞŝΥ>˹qæýýæýÞæý¹ý0ýÈĒÒ¹ĕæýÞ÷ŝăüďÒĜæĜæŖÒýŖæĒăýüÒýĜ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɪɣ'ĒăüDæÈãÒĜăqæÎÒĕďĒÒ¹ÎeĕÒ˹bãÒbğĒýæýÞUăæýĜÝăĒX¹ÎæăĜãÒĒ¹ďÒğĜæÈĕ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɪɪ¹ĕãUĒÒĕÒĒŖ¹ĜæăýæýĜãÒæăďã¹Ēü¹ÈÒğĜæȹ÷0ýÎğĕĜĒŝ˹D¹ŖæÞ¹ĜæýÞeýÈÒĒĜ¹æýĜŝ˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷˷ɢɡɧ About L.E.K. Consulting qÒ̲ĒÒ>˷˷=˷ăýĕğ÷ĜæýÞ˸¹Þ÷ăǹ÷ĕĜĒ¹ĜÒÞŝÈăýĕğ÷Ĝ¹ýÈŝŗăĒõæýÞŗæĜãÇğĕæýÒĕĕ÷Ò¹ÎÒĒĕĜăĕÒæŢÒÈăüďÒĜæĜæŖÒ¹ÎŖ¹ýĜ¹ÞÒ¹ýιüď÷æÝŝÞĒăŗĜã˷IğĒæýĕæÞãĜĕ¹ĒÒȹĜ¹÷ŝĕĜĕĜã¹ĜĒÒĕã¹ďÒĜãÒĜĒ¹ñÒÈĜăĒŝăÝăğĒÈ÷æÒýĜĕ̲ÇğĕæýÒĕĕÒĕ˸ğýÈăŖÒĒæýÞăďďăĒĜğýæĜæÒĕ¹ýÎÒüďăŗÒĒæýÞĜãÒüĜăü¹ĕĜÒĒĜãÒæĒüăüÒýĜĕăÝĜĒğĜã˷[æýÈÒɢɪɩɤ˸ăğĒŗăĒ÷ÎŗæÎÒďĒ¹ÈĜæÈÒ̝ĕď¹ýýæýÞĜãÒüÒĒæȹĕ˸ĕæ¹U¹ÈæÝæȹýÎğĒăďÒ̝ã¹ĕÞğæÎÒÎ÷Ò¹ÎÒĒĕ¹ÈĒăĕĕ¹÷÷æýÎğĕĜĒæÒĕÝĒăüÞ÷ăǹ÷ÈăĒďăĒ¹ĜæăýĕĜăÒüÒĒÞæýÞÒýĜĒÒďĒÒýÒğĒæ¹÷ÇğĕæýÒĕĕÒĕ¹ýÎďĒæŖ¹ĜÒÒđğæĜŝæýŖÒĕĜăĒĕ˷>ăăõæýÞÝăĒüăĒÒ˾pæĕæĜwww.lek.com˷ E XECUTIVE I NS IGHTS XÒÎÒƌýæýÞæăďã¹Ēü¹XΥUĒăÎğÈĜæŖæĜŝ˹DÒŗ0ýĕæÞãĜĕ¹ýÎ[ĜĒ¹ĜÒÞæÒĕ 1.ƐÈæÒýÈŝăÝĜãÒXΥÒýÞæýÒ˹Thismeasures the number of drug approvalsachieved per dollar invested in R&D. ItĒÒƍÒÈĜĕãăŗŗÒ÷÷¹Èăüď¹ýŝȹýÞÒýÒĒ¹ĜÒsuccessful outcomes from its researchÒƏăĒĜĕŗæĜãæý¹ÞæŖÒýÇğÎÞÒĜ˷ 0ýĜĒăÎğÈĜæăý R&D productivity stands as one of the mostcritical issues for biopharma executives, asit directly addresses the ability to transformpipeline investments into tangible revenuestreams. Despite its importance, assessingR&D productivity is notoriously challengingdue to the long innovation cycles and inherentuncertainties of drug development. 2.ƏÒÈĜæŖÒýÒĕĕăÝ÷¹ğýÈãÒĕ˹This assessesthe revenue generated per approved drug.It indicates the ability of a company tomaximize the commercial potential of itsproducts through successful market entry,commercialization strategies and lifecycle management. ĜæĜĕÈăĒÒ˸XΥďĒăÎğÈĜæŖæĜŝȹýÇÒÎÒƌýÒÎas the revenue generated per dollar o